Two firms act in record-breaking Australian biotech deal
by Sol Dolor | 03 Mar 2018
A global law firm and a leading independent Australian firm are providing legal expertise as an American pharmaceutical behemoth acquires a promising Australian cancer-research company.
Baker McKenzie is advising Merck & Co., known as Merck Sharp and Dohme (MSD) outside of North America, in its acquisition of Viralytics Limited. McCullough Robertson is acting for Viralytics, which has been a client since 2004.
David Holland, who heads the Asia-Pacific and Australian capital markets teams, is leading Baker McKenzie’s deal team. He is supported by senior associate Gabriella Plummer and a due diligence team with lawyers from most practice groups of the firm.
Capital markets partner Reece Walker and corporate partner Jim Peterson are leading the McCullough Robertson team. They are being assisted by senior associate Ben Wood and lawyer Naomi Benton. Partner Duncan Bedford is providing Australian Foreign Investment Review Board expertise, while partner Belinda Breakspear is handling IP matters.
The deal, which is subjects to customary conditions including shareholder, court, and regulatory approvals, is expected to close in June.
https://www.australasianlawyer.com....dbreaking-australian-biotech-deal-247284.aspx
Incredulous, page-97
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
